Brain Metastases Clinical Trials

42 studies are recruiting for brain metastases in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

   The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   New York-Presbyterian/Weill Cornell Medical Center, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT06072807 on ClinicalTrials.gov

2. REMASTer: REcurrent Brain Metastases After SRS Trial

   Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCLA, Los Angeles, California

   Locations

   9 in total

   Run by

   Monteris Medical

   See if you can join NCT05124912 on ClinicalTrials.gov

3. Development of MRF for Characterization of Brain Tumors After Radiotherapy

   The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced qua…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

   Locations

   2 in total

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06101069 on ClinicalTrials.gov

4. IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases

   This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   UF Health, Gainesville, Florida

   Run by

   University of Florida

   See if you can join NCT07569263 on ClinicalTrials.gov

5. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

6. Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

   This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05064280 on ClinicalTrials.gov

7. EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

   To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy. To learn if using SRS to treat all brain metastases that do not re…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06649058 on ClinicalTrials.gov

8. SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

   This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   2 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT04923542 on ClinicalTrials.gov

9. Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

   Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT07248228 on ClinicalTrials.gov

10. Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

    The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main questions it aims to answer are: 1. What are the dynamics of 18F-Flu…

    Stage

    EARLY_Phase 1

    Ages

    18 to 99

    Site

    Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona

    Run by

    University of Arizona

    See if you can join NCT06055790 on ClinicalTrials.gov

11. A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

    A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05048212 on ClinicalTrials.gov

12. Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

    standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07053033 on ClinicalTrials.gov

13. Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

    This is a randomized, phase II trial comparing staged stereotactic radiosurgery (SSRS) versus fractionated stereotactic radiotherapy (FSRT) in patients with large brain metastases (≥2 cm and ≤5 cm). The study aims to evaluate efficacy, safety, and tumor response between these two standard-of-care r…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT07227610 on ClinicalTrials.gov

14. Frameless Stereotactic Radiosurgery for Intact Brain Metastases

    This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT02747303 on ClinicalTrials.gov

15. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

    The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04899908 on ClinicalTrials.gov

16. Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

    To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ut Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT07139990 on ClinicalTrials.gov

17. MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

    Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and exper…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT04073966 on ClinicalTrials.gov

18. Phase I Study of Fractionated Stereotactic Radiation Therapy

    There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases. There has been no prospective dose escalation study performed to date to determine the maximum tolerated dose (MTD) in pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Montefiore Medical Center, The Bronx, New York

    Run by

    Albert Einstein College of Medicine

    See if you can join NCT03726359 on ClinicalTrials.gov

19. Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

    Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.

    Stage

    Not phased

    Ages

    19 and older

    Site

    University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06857006 on ClinicalTrials.gov

20. Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

    Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Locations

    2 in total

    Run by

    Medical College of Wisconsin

    See if you can join NCT05045950 on ClinicalTrials.gov

21. Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

    The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT05692635 on ClinicalTrials.gov

22. A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

    To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05673928 on ClinicalTrials.gov

23. Stereotactic Radiosurgery Dose Escalation for Brain Metastases

    This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Huntsman Cancer Institute, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT02390518 on ClinicalTrials.gov

24. A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

    The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05419076 on ClinicalTrials.gov

25. Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

    Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona

    Locations

    86 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT03550391 on ClinicalTrials.gov